Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

venous thromboembolism

- PMLiVE

FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine

Vaccine candidate demonstrated an overall efficacy of 66% in phase 3

- PMLiVE

GSK and CureVac look to develop next-generation mRNA COVID-19 vaccines

Novel mRNA vaccines will seek to combat newly emerging variants

- PMLiVE

Novartis, Bayer announce separate agreements to bolster COVID-19 vaccine manufacturing

Novartis will help manufacture Pfizer/BioNTech's vaccine and Bayer will do the same for CureVac's vaccine

- PMLiVE

J&J’s one-dose COVID-19 vaccine proves 66% effective in phase 3 trial

Vaccine was 57% effective against South African strain

Bayer symbol

Bayer’s finerenone scores FDA priority review for chronic kidney disease

FDA priority review is based on data from the phase 3 FIDELIO-DKD trial

- PMLiVE

CureVac and Bayer partner on mRNA-based COVID-19 vaccine

German pharma giant will support further development of CVnCoV

Bayer symbol

Bayer strengthens cell and gene therapy focus with new platform

Platform builds on previous acquisition deals for AskBio and BlueRock

Bayer symbol

Bayer pays an initial $2bn for gene therapy firm AskBio

Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates

- PMLiVE

Bayer’s drop of the future

Digital health isn’t always about digital

- PMLiVE

Janssen’s EGFR-targeting treatment regimen shows early benefit in lung cancer

Positive interim results presented at 2020 ESMO virtual congress

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

Merck, Bayer get FDA priority review for heart failure drug

Target action date set for January 2021

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links